Preemptive Etodolac for Pain Prevention after Traditional and Flapless Dental Implant Surgeries: A Double-Masked, Parallel-Group, Placebo-Controlled, Randomized Clinical Trial


KÖSE O. , ARABACI T., Çanakçı C. F. , Dilsiz A., KIZILDAG A.

FDI 101. CONGRESS, İstanbul, Turkey, 28 - 31 August 2013, pp.255-256

  • Publication Type: Conference Paper / Full Text
  • City: İstanbul
  • Country: Turkey
  • Page Numbers: pp.255-256

Abstract

Aim: This study aimed to investigate the effects of preemptive single
dose etodolac medication on pain prevention and patient comfort
following conventional flapped and flapless dental implant
surgeries.
Materials and methods: Thirty-two patients who had bilateral partial
or total tooth deficiency at their upper jaw were divided into
two groups. Half of the patients were selected for traditionalsurgery and others for flapless surgery. Each patient received etodolac,
600 mg, or placebo randomly 1 h before the surgeries. Pain
intensity and discomfort scores were recorded by participants
based on a visual analog scale and four-point verbal rating scale at
postoperative 1st, 2nd, 4th, 6th, 12th, 24th and 48th hours. Furthermore;
patients were suggested to use a rescue analgesic only if
the pain was intolerable, and to record it.
Results: Etodolac was superior to placebo in both traditional and flapless
surgery groups and results were more superior in flapless-etodolac
group especially at 2nd, 4th and 6th hours. Rescue medication use
was more excessive in traditional-placebo group than others. Moreover,
pain and discomfort scores and rescue medication using were
almost similar in traditional-etodolac and flapless-placebo groups.
Conclusion: The findings of this study suggest that the preemptive
single dose etodolac, 600 mg, medication was considerably effective
in the management of postoperative pain and discomfort following
both surgeries.